• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Castle Biosciences' Founder, President and CEO Derek Maetzold Honored with Prestigious Lifetime Achievement Award by The American Business Awards®

    6/4/25 7:00:00 AM ET
    $CSTL
    Medical Specialities
    Health Care
    Get the next $CSTL alert in real time by email

    Gold-level Stevie® Award recognizes Maetzold's transformative leadership in the healthcare industry, including molecular diagnostics and precision medicine

    2024-Derek-Maetzold-headshot

    FRIENDSWOOD, Texas, June 04, 2025 (GLOBE NEWSWIRE) -- Castle Biosciences, Inc. (NASDAQ:CSTL), a company improving health through innovative tests that guide patient care, today announced that its founder, president and chief executive officer Derek Maetzold has been awarded a distinguished Lifetime Achievement Award in the Management: Business Products Industries category in the 23rd Annual American Business Awards.

    The American Business Awards recognizes outstanding business performances in the United States. Also known as The Stevie Awards, for the Greek word meaning "crowned," the awards are presented in three tiers, with gold representing the highest level of achievement, followed by silver and bronze. More than 3,600 nominations from organizations of all sizes were submitted this year for consideration in a wide range of categories. The 2025 winners will be honored at a gala ceremony in New York on June 10.

    "Derek's vision and unwavering commitment to improving patient care have been the driving force behind Castle Biosciences' remarkable success story," said Frank Stokes, chief financial officer of Castle Biosciences. "Under his leadership, Castle has grown from a pioneering startup to an industry leader that is fundamentally changing how clinicians care for their patients.

    "What sets Derek apart is his rare combination of scientific expertise, business acumen and genuine passion for improving patient outcomes. He's built not just a successful company, but a purpose-driven organization with an extraordinary culture — as evidenced by our designation as a Top Workplace USA for four consecutive years."

    More than 250 professionals worldwide participated in the judging process to select this year's Stevie Award winners. A sampling of judges' comments regarding Derek's remarkable achievements are included below:

    • "Derek's leadership stands out for both its long-term vision and consistent execution. The business growth, clinical relevance and culture he has built at Castle Biosciences reflect a clear legacy."
    • "This nomination details a remarkable career dedicated to innovation in precision medicine. The founder's entrepreneurial spirit, strategic vision and significant patient impact are clear."
    • "Derek Maetzold has transformed Castle Biosciences into a leading molecular diagnostics company. His achievements are outstanding and have set new standards in the industry."



    "Organizations across the United States continue to demonstrate resilience and innovation," said Stevie Awards president Maggie Miller. "The 2025 Stevie winners have helped drive that success through their innovation, persistence and hard work. We congratulate all of the winners in the 2025 ABAs and look forward to celebrating their achievements during our June 10 gala event in New York."

    Details about the American Business Awards and the comprehensive list of 2025 Stevie winners are available here.

    About the Stevie Awards

    Stevie Awards are conferred in nine programs: the Asia-Pacific Stevie Awards, the German Stevie Awards, the Middle East & North Africa Stevie Awards, The American Business Awards®, The International Business Awards®, the Stevie Awards for Women in Business, the Stevie Awards for Great Employers, the Stevie Awards for Sales & Customer Service, and the Stevie Awards for Technology Excellence. Stevie Awards competitions receive more than 12,000 entries each year from organizations in more than 70 nations. Honoring organizations of all types and sizes and the people behind them, the Stevies recognize outstanding performances in the workplace worldwide. Learn more about the Stevie Awards at http://www.StevieAwards.com.

    About Castle Biosciences

    Castle Biosciences (NASDAQ:CSTL) is a leading diagnostics company improving health through innovative tests that guide patient care. The Company aims to transform disease management by keeping people first: patients, clinicians, employees and investors.

    Castle's current portfolio consists of tests for skin cancers, Barrett's esophagus and uveal melanoma. Additionally, the Company has active research and development programs for tests in these and other diseases with high clinical need, including its test in development to help guide systemic therapy selection for patients with moderate-to-severe atopic dermatitis seeking biologic treatment. To learn more, please visit www.CastleBiosciences.com and connect with us on LinkedIn, Facebook, X and Instagram. 

    DecisionDx-Melanoma, DecisionDx-CMSeq, i31-SLNB, i31-ROR, DecisionDx-SCC, MyPath Melanoma, TissueCypher, DecisionDx-UM, DecisionDx-PRAME and DecisionDx-UMSeq are trademarks of Castle Biosciences, Inc.

    Investor Contact:

    Camilla Zuckero

    [email protected]

    Media Contact:

    Allison Marshall

    [email protected]

    Source: Castle Biosciences Inc.

    A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/69d4d4ff-5716-401d-93ee-eccb787de1f3



    Primary Logo

    Get the next $CSTL alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $CSTL

    DatePrice TargetRatingAnalyst
    12/14/2023$25.00Buy
    Guggenheim
    1/5/2023$54.00Sector Outperform
    Scotiabank
    1/7/2022$59.00Overweight
    Stephens & Co.
    11/9/2021$85.00 → $75.00Outperform
    SVB Leerink
    7/14/2021$80.00 → $85.00Outperform
    SVB Leerink
    More analyst ratings

    $CSTL
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Castle Biosciences Honored with Multiple Top Workplaces Awards Recognizing the Company's Strong Culture

      FRIENDSWOOD, Texas, July 17, 2025 (GLOBE NEWSWIRE) -- Castle Biosciences, Inc. (NASDAQ:CSTL), a company improving health through innovative tests that guide patient care, today announced that it has earned multiple awards through the 2025 Top Workplaces program: a third consecutive national Healthcare Industry Top Workplaces award, with Castle ranking third among other recognized companies in its size bracket; a fourth consecutive regional Arizona Top Workplaces award from AZ Central; and consecutive national Top Workplaces Culture Excellence awards for Innovation, Work-Life Flexibility, Compensation & Benefits, Leadership and Purpose & Values. "Being recognized as a Top Workplace, ye

      7/17/25 7:00:00 AM ET
      $CSTL
      Medical Specialities
      Health Care
    • Castle Biosciences to Release Second Quarter 2025 Financial Results and Host Conference Call on Monday, Aug. 4, 2025

      FRIENDSWOOD, Texas, July 14, 2025 (GLOBE NEWSWIRE) -- Castle Biosciences, Inc. (NASDAQ:CSTL), a company improving health through innovative tests that guide patient care, today announced that it will release its financial results for the second quarter ended June 30, 2025, after the close of market on Monday, Aug. 4, 2025. Company management will host a conference call and webcast to discuss its financial results at 4:30 p.m. Eastern time on the same day. Conference Call and Webcast DetailsA live webcast of the conference call can be accessed here: https://events.q4inc.com/attendee/164444215, or via the webcast link on the Investor Relations page of the Company's website: https://ir.cast

      7/14/25 7:00:00 AM ET
      $CSTL
      Medical Specialities
      Health Care
    • Castle Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

      FRIENDSWOOD, Texas, June 19, 2025 (GLOBE NEWSWIRE) -- Castle Biosciences, Inc. (NASDAQ:CSTL), a company improving health through innovative tests that guide patient care, today announced that on June 14, 2025, the Compensation Committee of its Board of Directors granted restricted stock units (RSUs) to 66 employees covering an aggregate of 135,978 shares of common stock as an inducement material to their entering into employment with Castle Biosciences. The RSUs were granted pursuant to the Company's 2022 Inducement Plan in accordance with Nasdaq Listing Rule 5635(c)(4). The RSUs will vest over four years, with 25% of the shares vesting on the first anniversary of the applicable vesting c

      6/19/25 7:00:00 AM ET
      $CSTL
      Medical Specialities
      Health Care

    $CSTL
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Pres. & Chief Exec. Officer Maetzold Derek J sold $458,293 worth of shares (22,576 units at $20.30), decreasing direct ownership by 7% to 69,683 units (SEC Form 4)

      4 - CASTLE BIOSCIENCES INC (0001447362) (Issuer)

      7/1/25 4:05:26 PM ET
      $CSTL
      Medical Specialities
      Health Care
    • Director Cole G Bradley converted options into 8,673 shares, increasing direct ownership by 65% to 21,964 units (SEC Form 4)

      4 - CASTLE BIOSCIENCES INC (0001447362) (Issuer)

      5/23/25 5:01:17 PM ET
      $CSTL
      Medical Specialities
      Health Care
    • Director Bradbury Daniel converted options into 8,673 shares (SEC Form 4)

      4 - CASTLE BIOSCIENCES INC (0001447362) (Issuer)

      5/23/25 4:19:15 PM ET
      $CSTL
      Medical Specialities
      Health Care

    $CSTL
    Leadership Updates

    Live Leadership Updates

    See more
    • Castle Biosciences Kicks off Skin Cancer Awareness Month with a Ribbon Cutting to Celebrate the City of Friendswood's Designation as a Sun Safe Leadership Model City by IMPACT Melanoma

      The Company is proud to collaborate on a number of additional initiatives during the month of May Castle Biosciences, Inc. (NASDAQ:CSTL), a company improving health through innovative tests that guide patient care, today announced its support of key skin cancer advocacy events and initiatives throughout May in honor of Skin Cancer Awareness Month. The first such event is a ribbon cutting to honor the City of Friendswood's designation as a Sun Safe Leadership Model City — the first in Texas — by IMPACT Melanoma. The ribbon cutting will take place at Stevenson Park in Friendswood, Texas, on Friday, May 3, 2024, at 10:00 a.m. Central time. "Skin cancer is the most common cancer in the Unit

      4/30/24 4:30:00 PM ET
      $CSTL
      Medical Specialities
      Health Care
    • Persephone Biosciences Appoints Daniel Bradbury as Chair of the Board of Directors

      -Mr. Bradbury has over 35 years of experience leading fast-growing life sciences companies- Persephone Biosciences Inc., a biotechnology company reimagining patient health through the development of microbiome-based medicines, today announced that it has appointed Daniel Bradbury as Chair of the Board of Directors. "We are delighted to welcome Dan to our Board. His appointment reflects the recent progress we have made with our MyBabyBiome™ study of infant gut health, and our near-term plans to commercialize our first product based on the findings. Additionally, Persephone has a further two clinical studies underway, namely our ARGONAUT study of gut microbiome-linked immune modulation in

      10/23/23 8:00:00 AM ET
      $CSTL
      $EQ
      $ICPT
      Medical Specialities
      Health Care
      Biotechnology: Pharmaceutical Preparations
    • AltheaDx, Inc. appoints industry veteran Derek Maetzold to its Board of Directors

      SAN DIEGO, May 26, 2021  /PRNewswire/ -- AltheaDx, a commercial stage, precision medicine company with the world's leading pharmacogenomics test for anxiety and depression announced today that it has appointed Derek Maetzold to its Board of Directors. Mr. Maetzold is AltheaDx's fourth Director and brings not only strong knowledge of the diagnostics industry, but also operations and management experience. Mr. Maetzold is the Founder and CEO of publicly listed Castle Biosciences (NASDAQ:CSTL). Previously he held leadership roles at Encysive Pharmaceuticals, Amylin Pharmaceuticals, Sandoz and Schering-Plough. Castle Biosciences has gained Medicare reimbursement coverage and has had a successful

      5/26/21 12:42:00 PM ET
      $CSTL
      Medical Specialities
      Health Care

    $CSTL
    Financials

    Live finance-specific insights

    See more
    • Castle Biosciences to Release Second Quarter 2025 Financial Results and Host Conference Call on Monday, Aug. 4, 2025

      FRIENDSWOOD, Texas, July 14, 2025 (GLOBE NEWSWIRE) -- Castle Biosciences, Inc. (NASDAQ:CSTL), a company improving health through innovative tests that guide patient care, today announced that it will release its financial results for the second quarter ended June 30, 2025, after the close of market on Monday, Aug. 4, 2025. Company management will host a conference call and webcast to discuss its financial results at 4:30 p.m. Eastern time on the same day. Conference Call and Webcast DetailsA live webcast of the conference call can be accessed here: https://events.q4inc.com/attendee/164444215, or via the webcast link on the Investor Relations page of the Company's website: https://ir.cast

      7/14/25 7:00:00 AM ET
      $CSTL
      Medical Specialities
      Health Care
    • Castle Biosciences Reports First Quarter 2025 Results

      Q1 2025 revenue increased 21% over Q1 2024 to $88 million Q1 2025 total test reports for our core revenue drivers (DecisionDx®-Melanoma, DecisionDx®-SCC, TissueCypher®) increased 33% over Q1 2024 Raising full-year 2025 revenue guidance to $287-297 million from $280-295 million Conference call and webcast today at 4:30 p.m. ET FRIENDSWOOD, Texas, May 05, 2025 (GLOBE NEWSWIRE) -- Castle Biosciences, Inc. (NASDAQ:CSTL), a company improving health through innovative tests that guide patient care, today announced its financial results for the first quarter ended March 31, 2025. "We are pleased with the exceptional start to the year, marked by continued growth in test report volum

      5/5/25 4:06:00 PM ET
      $CSTL
      Medical Specialities
      Health Care
    • Castle Biosciences to Release First Quarter 2025 Financial Results and Host Conference Call on Monday, May 5, 2025

      FRIENDSWOOD, Texas, April 14, 2025 (GLOBE NEWSWIRE) -- Castle Biosciences, Inc. (NASDAQ:CSTL), a company improving health through innovative tests that guide patient care, today announced that it will release its financial results for the first quarter ended March 31, 2025, after the close of market on Monday, May 5, 2025. Company management will host a conference call and webcast to discuss its financial results at 4:30 p.m. Eastern time on the same day. Conference Call and Webcast DetailsA live webcast of the conference call can be accessed here: https://events.q4inc.com/attendee/787806709, or via the webcast link on the Investor Relations page of the Company's website: https://ir.cast

      4/14/25 7:00:00 AM ET
      $CSTL
      Medical Specialities
      Health Care

    $CSTL
    SEC Filings

    See more
    • SEC Form 144 filed by Castle Biosciences Inc.

      144 - CASTLE BIOSCIENCES INC (0001447362) (Subject)

      6/27/25 6:11:51 PM ET
      $CSTL
      Medical Specialities
      Health Care
    • Castle Biosciences Inc. filed SEC Form 8-K: Material Modification to Rights of Security Holders, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits

      8-K - CASTLE BIOSCIENCES INC (0001447362) (Filer)

      5/23/25 4:39:01 PM ET
      $CSTL
      Medical Specialities
      Health Care
    • Amendment: SEC Form SCHEDULE 13G/A filed by Castle Biosciences Inc.

      SCHEDULE 13G/A - CASTLE BIOSCIENCES INC (0001447362) (Subject)

      5/12/25 3:55:49 PM ET
      $CSTL
      Medical Specialities
      Health Care

    $CSTL
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Guggenheim initiated coverage on Castle Biosciences with a new price target

      Guggenheim initiated coverage of Castle Biosciences with a rating of Buy and set a new price target of $25.00

      12/14/23 6:54:55 AM ET
      $CSTL
      Medical Specialities
      Health Care
    • Scotiabank initiated coverage on Castle Biosciences with a new price target

      Scotiabank initiated coverage of Castle Biosciences with a rating of Sector Outperform and set a new price target of $54.00

      1/5/23 7:53:37 AM ET
      $CSTL
      Medical Specialities
      Health Care
    • Stephens & Co. initiated coverage on Castle Biosciences with a new price target

      Stephens & Co. initiated coverage of Castle Biosciences with a rating of Overweight and set a new price target of $59.00

      1/7/22 5:42:05 AM ET
      $CSTL
      Medical Specialities
      Health Care

    $CSTL
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Castle Biosciences Inc.

      SC 13G/A - CASTLE BIOSCIENCES INC (0001447362) (Subject)

      11/14/24 4:40:39 PM ET
      $CSTL
      Medical Specialities
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Castle Biosciences Inc.

      SC 13G/A - CASTLE BIOSCIENCES INC (0001447362) (Subject)

      11/13/24 6:44:33 PM ET
      $CSTL
      Medical Specialities
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Castle Biosciences Inc.

      SC 13G/A - CASTLE BIOSCIENCES INC (0001447362) (Subject)

      7/8/24 4:32:39 PM ET
      $CSTL
      Medical Specialities
      Health Care